The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application
Abstract
The introduction of the first antipsychotic drug, chlorpromazine, was a milestone for psychiatry. The authors review the history, classification, indications, mechanism, efficacy, side effects, dosing, drug initiation, switching, and other practical issues and questions related to antipsychotics. Classifications such as first-generation/typical versus second-generation/atypical antipsychotics are neither valid nor useful; these agents should be described according to the Neuroscience-based Nomenclature (NbN). Antipsychotic drugs are not specific for treating schizophrenia. They reduce psychosis regardless of the underlying diagnosis, and they go beyond nonspecific sedation. All currently available antipsychotic drugs are dopamine blockers or dopamine partial agonists. In schizophrenia, effect sizes for relapse prevention are larger than for acute treatment. A major unresolved problem is the implausible increase in placebo response in antipsychotic drug trials over the decades. Differences in side effects, which can be objectively measured, such as weight gain, are less equivocal than differences in rating-scale-measured (subjective) efficacy. The criteria for choosing among antipsychotics are mainly pragmatic and include factors such as available formulations, metabolism, half-life, efficacy, and side effects in previous illness episodes. Plasma levels help to detect nonadherence, and once-daily dosing at night (which is possible with many antipsychotics) and long-acting injectable formulations are useful when adherence is a problem. Dose-response curves for both acute treatment and relapse prevention follow a hyperbolic pattern, with maximally efficacious average dosages for schizophrenia of around 5 mg/day risperidone equivalents. Computer apps facilitating the choice between drugs are available. Future drug development should include pharmacogenetics and focus on drugs for specific aspects of psychosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., & Wang, P. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091379 · Cited by 7,067
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Self-citationSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationHuhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Self-citationAntipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301
Research works printed but not linked: 14
- Laborit H, 1952, Presse Med (1893), 60, 206
- Davis JM, 1985, J Clin Psychiatry, 46, 18
- Haase HJ, 1954, Der Nervenarzt, 25, 486
- Haase HJ, 1983, Der Neuroleptika Dosierung Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker
- Abraham D, 1996, Psychiatr Prax, 23, 109
- Komossa K, 2010, Cochrane Database Syst Rev, 12, CD008121
- Meltzer HY, 1989, Psychopharmacol Bull, 25, 390
- Schoemaker H, 1997, J Pharmacol Exp Ther, 280, 83
- Wu H, 2024, Cochrane Database Syst Rev, 2, CD015665
- Smith RC, 1975, Psychopharmacol Commun, 1, 285
- Sampson S, 2013, Cochrane Database Syst Rev, 7, CD006196
- World Health Organization, 2023, WHO Model List of Essential Medicines: 23rd List, 2023
- Feber L, JAMA Psychiatry
- Foucault M, 1961, Folie et déraison: Histoire de la folie à l’âge classique
Cited by
Leucht, S., Siafis, S., McGrath, J. J., McGorry, P. D., Howes, O. D., Tamminga, C. A., Carr, R., Bighelli, I., Schneider‐Thoma, J., Priller, J., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00667-6 · Cited by 81
Self-citationBiso, L., Carli, M., Scarselli, M., & Longoni, B. (2025) · Biomedicines · doi:10.3390/biomedicines13010085 · Cited by 22
“Antipsychotics are also indicated for the treatment of mood disorders, and they are used for different conditions and in various populations (including the pediatric and the elderly populations), both in approved and off-label settings [3–7].”
Zhao, G., Sun, Y., Zhang, Y., Lu, T., Lu, Z., Kang, Z., Schneider‐Thoma, J., Xie, W., Yang, Y., Guo, J., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250111 · Cited by 20
Self-citationPriming the Liver Endocytic Pathway to Accelerate Hepatobiliary Clearance of Nanoparticles
Ren, Y., Mei, F., Lu, H., Liang, Y., Zheng, R., Wang, Z., Liang, F., Du, B., & Jiang, X. (2026) · ACS Nano · doi:10.1021/acsnano.5c20532 · Cited by 12
IUPHAR review – Novel therapeutic targets for schizophrenia treatment: A translational perspective
Begni, V., Marchesin, A., & Riva, M. A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107690 · Cited by 14
Metadata
- Authors
- Leucht, S., Priller, J., & Davis, J. M.
- Affiliations
- TUM Klinikum (DE)
- Venue
- American Journal of Psychiatry
- Published
- 2024-10-01
- Volume
- 181
- Issue
- 10
- Pages
- 865-878
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4403006239
- Cited by
- 117
- References
- 133
- Citations by year
- 2026: 65 · 2025: 50 · 2024: 2
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- DZNE Pub (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- antipsychotic drugs, chlorpromazine, typical antipsychotics, atypical antipsychotics, dopamine antagonists, partial dopamine agonist, schizophrenia, psychosis, relapse prevention, placebo response, antipsychotic adverse effects, weight gain, medication adherence, long-acting injectable antipsychotics, once-daily dosing, dose-response relationship, pharmacogenetics, antipsychotic selection
- MeSH terms
- Humans, Schizophrenia, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application. https://app.cochat.ai/papers/10.1176/appi.ajp.20240738
- The paper
- Leucht, S., Priller, J., & Davis, J. M. (2024). Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.20240738
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.